Settled!?
25/06/20 -"Bayer’s management will take a lot of money off its hands trying to settle three litigations in the US, of which the RoundUp one will be the most expensive. With this move, Bayer lifts some ..."
Pages
73
Language
English
Published on
25/06/20
You may also be interested by these reports :
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...
10/09/26
After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of ...
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...